Correlation Between HCW Biologics and ESSA Pharma
Can any of the company-specific risk be diversified away by investing in both HCW Biologics and ESSA Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining HCW Biologics and ESSA Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between HCW Biologics and ESSA Pharma, you can compare the effects of market volatilities on HCW Biologics and ESSA Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in HCW Biologics with a short position of ESSA Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of HCW Biologics and ESSA Pharma.
Diversification Opportunities for HCW Biologics and ESSA Pharma
-0.07 | Correlation Coefficient |
Good diversification
The 3 months correlation between HCW and ESSA is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding HCW Biologics and ESSA Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ESSA Pharma and HCW Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on HCW Biologics are associated (or correlated) with ESSA Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ESSA Pharma has no effect on the direction of HCW Biologics i.e., HCW Biologics and ESSA Pharma go up and down completely randomly.
Pair Corralation between HCW Biologics and ESSA Pharma
Given the investment horizon of 90 days HCW Biologics is expected to generate 3.75 times more return on investment than ESSA Pharma. However, HCW Biologics is 3.75 times more volatile than ESSA Pharma. It trades about 0.04 of its potential returns per unit of risk. ESSA Pharma is currently generating about -0.05 per unit of risk. If you would invest 109.00 in HCW Biologics on August 30, 2024 and sell it today you would lose (59.00) from holding HCW Biologics or give up 54.13% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
HCW Biologics vs. ESSA Pharma
Performance |
| Timeline |
| HCW Biologics |
| ESSA Pharma |
HCW Biologics and ESSA Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with HCW Biologics and ESSA Pharma
The main advantage of trading using opposite HCW Biologics and ESSA Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if HCW Biologics position performs unexpectedly, ESSA Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ESSA Pharma will offset losses from the drop in ESSA Pharma's long position.| HCW Biologics vs. Anebulo Pharmaceuticals | HCW Biologics vs. Rezolute | HCW Biologics vs. Eliem Therapeutics | HCW Biologics vs. Molecular Partners AG |
| ESSA Pharma vs. Ikena Oncology | ESSA Pharma vs. Eliem Therapeutics | ESSA Pharma vs. HCW Biologics | ESSA Pharma vs. Tempest Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Complementary Tools
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |